Jeny M. Maier
Managing Partner
Jeny Maier is Axinn’s managing partner and a trusted advisor for Fortune 500 companies navigating the complexities of antitrust law in high-profile, multibillion-dollar deals. With two decades of experience, Jeny stands out for her strategic approach and profound knowledge, earning recognition from Chambers USA and The Legal 500 U.S. as a leading figure in antitrust and competition law.
Jeny M. Maier
Managing Partner
Jeny Maier is Axinn’s managing partner and a trusted advisor for Fortune 500 companies navigating the complexities of antitrust law in high-profile, multibillion-dollar deals. With two decades of experience, Jeny stands out for her strategic approach and profound knowledge, earning recognition from Chambers USA and The Legal 500 U.S. as a leading figure in antitrust and competition law.
In her practice, Jeny guides clients throughout the complete life cycle of transactions, from risk analysis and due diligence to pre merger notifications and merger agreement negotiations through antitrust agency review, investigations, and remedies.
Jeny leverages her background in economics to strategically assess commercial negotiations, regulatory risks, and advocacy opportunities related to high-profile deals. She represents clients across industries, including the healthcare, pharmaceuticals, technology, and manufacturing sectors. Her experience includes advising Sunrun – a major provider of residential solar, battery storage, and energy services – on its transformational $3.2 billion acquisition of Vivint Solar, as well as representing McKesson in its $2.49 billion acquisition of a controlling interest in Florida Cancer Specialists’ Core Ventures.
Beyond deal-making, Jeny has considerable experience representing clients in civil and criminal antitrust investigations and related class action litigation. She also advises clients on antitrust issues relating to pricing practices, distribution and marketing arrangements, intellectual property license agreements, and standard-setting activities.
As managing partner at Axinn, Jeny leverages her strong business acumen to drive strategy and implement Firm-wide initiatives. Before joining Axinn’s Executive Committee in 2022, she held leadership roles within the Firm’s antitrust group and led the Women’s Affinity Group. Jeny also contributes to the broader legal community as vice chair of the American Bar Association Antitrust Law Section’s Serial Podcast Committee.
Experience
Mergers and Acquisitions
- Representing McKesson in numerous matters, including a joint venture combining its U.S. Oncology Research and HCA Healthcare Inc.’s Sarah Cannon Research Institute, its $875 million acquisition of Rx Savings Solutions, its $1.4 billion acquisition of CoverMyMeds, its $800 million acquisition of Medical Specialties Distributors (MSD), its $735 million acquisition of RxCrossRoads from CVS, its acquisitions of Labsco and Biologics, and its sale of Enterprise Information Solutions to Allscripts. Also secured clearance for McKesson’s $3.4 billion healthcare technology joint venture with Change Healthcare, which was unconditionally cleared after a Second Request investigation.
-
Represented Take-Two Interactive Software, Inc., in its $12.7 billion acquisition of Zynga.
-
Represented Dell Technologies Inc. in its $4 billion sale of Boomi.
-
Represented Tufts Health Plan in its merger with Harvard Pilgrim Health Care.
-
Represented Sunrun in its $3.2 billion acquisition of Vivint Solar, securing clearance without a second request investigation.
-
Lead global coordinating antitrust counsel to Dell Inc. in its $67 billion acquisition of EMC Corporation.
-
Global antitrust lead counsel to Johnson Controls in the $2 billion sale of its Scott Safety business to 3M.
-
Represented Stanley Black & Decker, Inc., in its $900 million purchase of the Craftsman brand from Sears Holdings Corporation.
-
Obtained clearance for Charles River Laboratories’ $585 million acquisition of WIL Research Laboratories.
-
Represented Tyler Technologies Inc. in its $670 million acquisition of New World Systems Corporation.
Honors
- Chambers USA, District of Columbia: Antitrust (2024)
- The Legal 500 United States, Antitrust: Merger Control (2024)
- Lawdragon, "500 Leading Dealmakers in America" (2024 – 2025)
- The Legal 500 United States, "Bright Rising Star" in Antitrust Law (2014)
- Who's Who Legal, Competition (2024)
- Who’s Who Legal: Competition Future Leaders (2017 – 2022)
- Profiles in Diversity Journal, "Women Worth Watching" (2018)
Education
- JD – The George Washington University Law School (2005)
- BS – Georgetown University (2000)
Admissions
- District of Columbia
- New York
- U.S. District Court District of Columbia
- U.S. District Court Eastern District of New York
- U.S. District Court Southern District of New York
Quotes
Jeny provides a very good balance of both technical antitrust expertise and the ability to explain things and provide nuanced analysis to non-legal professionals.
Chambers USA
Jeny Maier is also a key figure, with expertise in tech and healthcare.
The Legal 500 United States
She stands out from her peers due to her pragmatic approach and outstanding client care.
Who's Who Legal
Garners praise as "an excellent attorney and a wonderful person," and has extensive experience counselling clients in complex M&A transactions.
News & Insights
News & Insights
What Trump’s FTC Picks Mean for Bio-Pharma Dealmaking and PBMs
Media Mentions
Antitrust
AIC General Counsel Day 2024
Speaking Engagement
Antitrust
Axinn Partners Named to Lawdragon 500 Leading Dealmakers in America 2025
Awards & Recognitions
Antitrust
Axinn Achieves Mansfield Certification from Diversity Lab for 2023-2024
Diversity, Equity & Inclusion
Corporate Counsel Women, Influence, & Power In Law Conference 2024
Speaking Engagement
Antitrust
Axinn Advises McKesson in Securing Controlling Interest in Core Ventures
Deals & Cases
Antitrust
Who's Who Legal Recognizes Twelve Axinn Attorneys
Awards & Recognitions
Antitrust
ACI 11th Annual Women Leaders in Life Sciences Law Conference
Speaking Engagement
Antitrust
Has the Scrutiny Reached a Fever Pitch? Taking the Temperature of Private Equity in Healthcare
Podcast
Antitrust
FTC Gears Up For Busy 2024 Merger Summer & Fall
Media Mentions
Antitrust